Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, Devanand DP, Weintraub D, McEvoy B, Youakim JM, Stankovic S, Foff EP.
Tariot PN, et al.
N Engl J Med. 2021 Jul 22;385(4):309-319. doi: 10.1056/NEJMoa2034634.
N Engl J Med. 2021.
PMID: 34289275
Clinical Trial.
The effects of the oral 5-HT(2A) inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. ...During the double-blind phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin group and in 41 …
The effects of the oral 5-HT(2A) inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are n …